A nationwide multi-institutional retrospective study to identify prognostic factors and develop a graded prognostic assessment system for patients with brain metastases from uterine corpus and cervical cancer

BMC Cancer

Research Article

Fumi Higuchi¹  Takeshi Okuda²  Keishi Makino³  Hideaki Takahashi⁴  Masatoshi Takagaki⁵  Yoshiko Okita⁶  Jiro Akimoto⁷  Yasuyuki Hirashima⁸  Yuzo Hasegawa⁹  Yoshitaka Narita^1,10  Masamichi Takahashi^1,10  Koichi Mitsuya^1,11  Yoko Nakasu^1,11  Nakamasa Hayashi^1,11 

[1]Department of Neurosurgery, Dokkyo Medical University, 321-0293, Tochigi, Japan

[2]Department of Neurosurgery, Kinki University, 589-8511, Osaka, Japan

[3]Department of Neurosurgery, Kumamoto University, 860-8555, Kumamoto, Japan

[4]Department of Neurosurgery, Niigata Cancer Center Hospital, 951-8666, Niigata, Japan

[5]Department of Neurosurgery, Osaka Medical Center for Cancer and Cardiovascular disease, 537-8511, Osaka, Japan

[6]Department of Neurosurgery, Osaka National Hospital, 540-0006, Osaka, Japan

[7]Department of Neurosurgery, Tokyo Medical University, 160-8402, Tokyo, Japan

[8]Division of Gynecology, Shizuoka Cancer Center Hospital, 411-8777, Shizuoka, Japan

[9]Division of Neurological Surgery, Chiba Cancer Center, 260-8717, Chiba, Japan

[10]Division of Neurosurgery, National Cancer Center, 104-0045, Tokyo, Japan

[11]Division of Neurosurgery, Shizuoka Cancer Center Hospital, Nagaizumi, 411-8777, Shizuoka, Japan

关键词: Brain metastasis;    Graded prognostic assessment;    Radiation;    Surgery;    Uterine cervical cancer;    Uterine corpus cancer;   

DOI  :  10.1186/s12885-017-3358-6

 received in 2016-12-01, accepted in 2017-05-15,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundThe prevalence of brain metastases (BM) from uterine cancer has recently increased because of the improvement of overall survival (OS) of patients with uterine cancer due to its early detection and improved local control as a result of new effective treatments. However, little information is available regarding their clinical characteristics and prognosis, because oncologists have encountered BM from uterine cancer on rare occasions.MethodsRecords from 81 patients with uterine BM were collected from 10 institutes in Japan. These were used in a multi-institutional study to identify prognostic factors and develop a graded prognostic assessment (GPA) for patients with BM from uterine cancer.ResultsMedian OS after the development of BM was 7 months (95% confidence interval, 4 to 10 months). Multivariate analysis revealed that there were survival differences according to the existence of extracranial metastases and number of BM. In the present uterine-GPA, a score of 0 was assigned to those patients with ≥5 BM and extracranial metastasis, a score of 2 was assigned to those patients with one to four BM or without extracranial metastasis, and a score of 4 was assigned to those patients with one to four BM and without extracranial metastasis. The median OS for patients with a uterine-GPA scores of 0, 2, and 4 was 3, 7, and 22 months, respectively. A survival analysis confirmed the presence of statistically significant differences between these groups (p < 0.05). The results were validated by data obtained from the National Report of Brain Tumor Registry of Japan.ConclusionUterine GPA incorporates two simple clinical parameters of high prognostic significance and can be used to predict the expected survival times in patients with BM from uterine cancer. Its use may help in determining an appropriate treatment for individual patients with BM.

【 授权许可】

CC BY   
© The Author(s). 2017